Deanna L. Kelly, PharmD, BCPP: Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Name: Deanna L. Kelly, PharmD, BCPP: Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations
SKU: 3279
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 35 No. 4 Articles Tags: antipsychotic, deanna-l-kelly, medworks-media, pharmacodynamic, pharmacokinetic, psychopharmacology-bulletin, qtc-interval, raymond-c-love, torsades-de-pointes, ziprasidone

Description

Deanna L. Kelly, PharmD, BCPP: Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Description

Deanna L. Kelly, PharmD, BCPP

DRUG INTERACTIONS

Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Deanna L. Kelly, PharmD, BCPP, and Raymond C. Love, PharmD, BCPP, FASHP

Zonisamide for Bipolar Depression by Deborah Dauphinais

Euprolactinemic Gynecomastia and Galactorrhea with Risperidone-Fluvoxamine Combination by Samir Kumar Praharaj

Assessment of Anxiety in Clinical Trials with Depressed Patients

What Mood Symptoms may be most Difficult to Rate?

Deanna L. Kelly, PharmD, BCPP: Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Description

Deanna L. Kelly, PharmD, BCPP

DRUG INTERACTIONS

Ziprasidone and the QTc Interval: Pharmacokinetic and Pharmacodynamic Considerations

Deanna L. Kelly, PharmD, BCPP, and Raymond C. Love, PharmD, BCPP, FASHP

Related products

Zonisamide for Bipolar Depression by Deborah Dauphinais

Euprolactinemic Gynecomastia and Galactorrhea with Risperidone-Fluvoxamine Combination by Samir Kumar Praharaj

Assessment of Anxiety in Clinical Trials with Depressed Patients

What Mood Symptoms may be most Difficult to Rate?